Travere Therapeutics, Inc.
A biopharmaceutical company focused on developing and commercializing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is FDA-approved to slow kidney function decline in adults with a rare kidney disease called primary IgA nephropathy, and the company also sells Thiola and Thiola EC for the kidney stone condition cystinuria. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for the rare metabolic disorder classical HCU.
Bought 540.5K · Sold 1.76M
Granted 1.12M · Sold 749.3K
Granted 314.7K · Bought 15.6K · Sold 348.8K
Granted 100.0K · Bought 1.1K
Sold 71.7K
Granted 208.6K · Sold 76.7K
Granted 149.8K · Sold 59.9K
Granted 281.6K · Sold 176.5K
Granted 191.4K · Sold 78.1K
Granted 334.7K · Sold 231.0K
Granted 150.0K · Sold 50.0K
Granted 20.0K · Bought 10.1K
Granted 100.0K · Bought 2.2K · Sold 10.4K
Granted 109.5K · Bought 30.0K · Sold 48.0K
Granted 109.5K · Sold 48.0K
Granted 58.5K · Sold 31.3K
Sold 20.0K
Granted 62.0K · Sold 16.5K
Granted 129.0K · Sold 87.5K
Granted 211.9K · Sold 199.7K
Granted 39.4K
Granted 39.4K
Granted 117.9K · Sold 82.2K
Granted 34.0K
Granted 32.8K
Granted 24.5K
Granted 29.0K
Granted 24.0K · Bought 5.0K
Granted 29.0K
Granted 49.2K · Sold 24.5K
Granted 5.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Shepley Ruth10% owner · 1 transaction | — | 49.00Mas of Oct 2007 | — | — | — |
| Shkreli MartinFmr Officer Dir 10% Sharehldr · 53 transactions | — | 1.77Mas of Nov 2014 | — | 540.5K | 1.76M |
| Dube Eric MCHIEF EXECUTIVE OFFICER, Director · 68 transactions | — | 432.9K | 1.12M | — | 749.3K |
| Aselage SteveDirector · 73 transactions | — | 347.7Kas of May 2022 | 314.7K | 15.6K | 348.8K |
| Panoff Marc LChief Financial Officer · 2 transactions | — | 221.1Kas of Feb 2014 | 100.0K | 1.1K | — |
| Shih AlvinEVP of Research & Development · 8 transactions | — | 158.3Kas of Sep 2016 | — | — | 71.7K |
| Heerma PeterCHIEF COMMERCIAL OFFICER · 45 transactions | — | 140.7K | 208.6K | — | 76.7K |
| Cline Christopher R.CHIEF FINANCIAL OFFICER · 37 transactions | — | 118.7K | 149.8K | — | 59.9K |
| Rote William E.Chief Research Officer · 79 transactions | — | 115.5K | 281.6K | — | 176.5K |
| Inrig JulaCHIEF MEDICAL OFFICER · 36 transactions | — | 112.8K | 191.4K | — | 78.1K |
| Reed Elizabeth EChief Legal Officer and GC · 100 transactions | — | 105.2K | 334.7K | — | 231.0K |
| Valeur Jensen Margaret EGeneral Counsel · 4 transactions | — | 100.0Kas of Feb 2016 | 150.0K | — | 50.0K |
| Richardson Steven GaryDirector · 4 transactions | — | 99.1Kas of Dec 2014 | 20.0K | 10.1K | — |
| Plotkin HoracioChief Medical Officer · 4 transactions | — | 91.8Kas of Dec 2014 | 100.0K | 2.2K | 10.4K |
| Meckler Jeffrey ADirector · 20 transactions | — | 91.5K | 109.5K | 30.0K | 48.0K |
| Lyons Gary ADirector · 18 transactions | — | 61.5K | 109.5K | — | 48.0K |
| Coughlin TimothyDirector · 13 transactions | — | 56.3K | 58.5K | — | 31.3K |
| Paley JeffreyDirector · 1 transaction | — | 51.7Kas of Aug 2014 | — | — | 20.0K |
| Rosenberg Noah L.Chief Medical Officer · 26 transactions | — | 47.6Kas of Aug 2021 | 62.0K | — | 16.5K |
| Baynes Roy D.Director · 30 transactions | — | 46.0K | 129.0K | — | 87.5K |
| Calvin SandraSVP, CHIEF ACCOUNTING OFFICER · 47 transactions | — | 42.4K | 211.9K | — | 199.7K |
| Orwin John ADirector · 10 transactions | — | 39.4K | 39.4K | — | — |
| Squarer RonDirector · 10 transactions | — | 39.4K | 39.4K | — | — |
| Clague LauraChief Financial Officer · 51 transactions | — | 35.7Kas of May 2022 | 117.9K | — | 82.2K |
| Poole SandraDirector · 8 transactions | — | 34.0K | 34.0K | — | — |
| Bruhn Suzanne LouiseDirector · 7 transactions | — | 32.8K | 32.8K | — | — |
| Williams Brinkley RuthDirector · 5 transactions | — | 29.8K | 24.5K | — | — |
| Coughlin Timothy PDirector · 5 transactions | — | 29.0Kas of May 2019 | 29.0K | — | — |
| Golding Cornelius EDirector · 5 transactions | — | 29.0Kas of May 2016 | 24.0K | 5.0K | — |
| Kozarich John WDirector · 5 transactions | — | 29.0Kas of May 2019 | 29.0K | — | — |
| McFarlane Neil F.Chief Operating Officer · 12 transactions | — | 27.0Kas of May 2019 | 49.2K | — | 24.5K |
| Brinkley Ruth WilliamsDirector · 1 transaction | — | 5.3Kas of Sep 2021 | 5.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -3.57M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.